-
公开(公告)号:US11028075B2
公开(公告)日:2021-06-08
申请号:US16283451
申请日:2019-02-22
Applicant: GENENTECH, INC.
Inventor: Daniel Sutherlin , Steven McKerrall , Kwong Wah Lai , Zhiguo Liu , Wenfeng Liu , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Liang Zhao , Claudio Sturino
IPC: C07D413/12 , C07D403/12 , C07D233/96 , C07D401/12 , A61P17/04 , C07D263/52 , C07D305/06 , C07D401/14 , A61K31/506 , A61K31/538 , C07B59/00 , A61K31/63 , A61K45/06 , C07D239/69 , A61K31/505
Abstract: The invention provides benzene sulfonamides and pharmaceutically acceptable salt thereof that are useful as sodium channel blockers for the treatment of, for example, pain. The following compound is illustrative:
-
公开(公告)号:US10457654B2
公开(公告)日:2019-10-29
申请号:US15799771
申请日:2017-10-31
Applicant: GENENTECH, INC. , XENON PHARMACEUTICALS INC.
Inventor: Daniel Sutherlin , Steven McKerrall , Michael Scott Wilson , Kwong Wah Lai , Philippe Bergeron , Birong Zhang , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Liang Zhao , Claudio Sturino
IPC: C07D285/08 , C07D277/52 , C07D239/69 , C07D213/76 , C07D261/16 , C07D401/12 , C07D403/12 , C07D417/12 , A61K31/427 , A61P19/02 , A61P29/00
Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
-
公开(公告)号:US10968203B2
公开(公告)日:2021-04-06
申请号:US15989008
申请日:2018-05-24
Inventor: Marie-Gabrielle Braun , Paul Gibbons , Wendy Lee , Cuong Ly , Joachim Rudolph , Jacob Schwarz , Avi Ashkenazi , Leo Fu , Tommy Lai , Fei Wang , Ramsay Beveridge , Liang Zhao
IPC: A61K31/506 , A61K45/06 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61P35/00
Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
4.
公开(公告)号:US20180265497A1
公开(公告)日:2018-09-20
申请号:US15989008
申请日:2018-05-24
Inventor: Marie-Gabrielle Braun , Paul Gibbons , Wendy Lee , Cuong Ly , Joachim Rudolph , Jacob Schwarz , Avi Ashkenazi , Leo Fu , Tommy Lai , Fei Wang , Ramsay Beveridge , Liang Zhao
IPC: C07D401/14 , A61K31/506 , C07D401/04 , C07D405/14 , C07D417/14 , C07D413/14 , A61K45/06
CPC classification number: C07D401/14 , A61K31/506 , A61K45/06 , A61P35/00 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号:US12275745B2
公开(公告)日:2025-04-15
申请号:US18057742
申请日:2022-11-21
Applicant: Genentech, Inc.
Inventor: Jason Robert Zbieg , Paul Powell Beroza , Vishal Anil Verma , Bing-Yan Zhu , Ramsay Beveridge , Liang Zhao , Melissa Leblanc , Lisa Marie Barton , Bryan Ka Ip Chan , Samir Bouayad-Gervais , Anwesha Dey , Marie Anne Evangelista , Russell Tyler Smith
IPC: C07D513/04 , C07D215/12 , C07D235/14 , C07D239/74 , C07D241/42 , C07D263/56 , C07D307/81 , C07D403/06 , C07D405/08 , C07D413/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D498/04
Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
-
-
-
-